Further knowledge on the downstream molecular mechanisms, that lead CD99 to modify the cellular actin dynamics, may also enable the identification of other druggable targets for combinatorial therapy and to better improve the outcome of this dreadful tumor. This evidence concerns the gene CD99 and neoplasm.